文献速递瓣膜外科

经环二尖瓣桥植入持续减少二尖瓣反流:2年耐久性与有效性前瞻性试验结果

Persistent reduction of mitral regurgitation by implantation of a transannular mitral bridge: durability and effectiveness of the repair at 2 years-results of a prospective trial†.
PubMed 文献 · Eur J Cardiothorac Surg · 2019-01-01

该前瞻性单中心试验纳入34例功能性二尖瓣反流患者,手术植入二尖瓣桥直接缩小瓣环间隔-侧径。2年时二尖瓣反流从3.32±0.47降至0.50±0.83(P≤0.001),33/34例反流≤1+,无卒中或器械相关不良事件,提示该技术可行、安全且有效。

要点

  • 二尖瓣桥直接缩小瓣环间隔-侧径,2年时二尖瓣反流显著且持续减少。
  • 2年时33/34例反流≤1+,4例因瓣周复发反流≥3再次干预,无器械取出或常规瓣膜修复/置换。
  • 2年时平均二尖瓣跨瓣压差2.15±0.82 mmHg,左室射血分数和NYHA心功能分级均改善。

核心结论

  • 单中心试验数据表明,经环二尖瓣桥直接缩小瓣环间隔-侧径对功能性二尖瓣反流患者可行、安全且有效。
  • 需在更大样本中验证并与传统瓣环成形环进行比较。

研究设计与样本

  • 前瞻性单中心试验,连续纳入34例功能性二尖瓣反流患者,手术植入二尖瓣桥。
  • 主要终点为植入后1、3、6个月二尖瓣反流≤1+,以及免于后续二尖瓣修复或置换。

主要发现

  • 34例中32例(94.1%)达到主要终点,6个月时二尖瓣反流≤1+。
  • 2年时二尖瓣反流从3.32±0.47降至0.50±0.83(P≤0.001),33/34例反流≤1+。
  • 2年时无卒中或器械相关不良事件;4例因瓣周复发性反流≥3再次干预,无二尖瓣桥取出或常规二尖瓣修复/置换。
  • 2年时平均二尖瓣跨瓣压差2.15±0.82 mmHg;二尖瓣环间隔-侧径从40.4±2.91 mm降至28.9±1.55 mm(P≤0.001)。
  • 2年时左室射血分数从57.9±10.4%升至62.4±9.7%(P≤0.001),NYHA心功能分级从2.19±0.76改善至1.41±0.61(P≤0.001)。

临床怎么用

  • 对于功能性二尖瓣反流患者,经环二尖瓣桥直接缩小瓣环间隔-侧径可作为一种实现持续反流减少的手术选择。
  • 术后2年内需关注瓣周复发性反流,必要时再次干预,但无需取出二尖瓣桥或行常规二尖瓣修复/置换。

局限性

  • 单中心、小样本(34例)试验,结果需在更大样本中验证。
  • 未与传统瓣环成形环进行对照比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Ring annuloplasty reduces the septal-lateral diameter (SLD) indirectly by circumferential annular cinching and frequently results in the recurrence of mitral regurgitation (MR) in patients with functional MR (FMR). Our goal was to report the results from the trial and the 2-year post-trial surveillance data. We evaluated whether direct reduction of the SLD with a transannular mitral bridge could achieve significant and durable MR reduction in patients with FMR. METHODS: In a prospective trial, 34 consecutive patients with FMR had a mitral bridge implanted surgically. Primary end points were MR ≤1+ at 1, 3 and 6 months postimplant and freedom from subsequent surgical mitral valve repair or replacement. RESULTS: Thirty-two of 34 (94.1%) patients met the primary end points with MR ≤1+ at 6 months. At 2 years, there were no strokes or device-related adverse events. At 2 years, MR was reduced from 3.32 ± 0.47 to 0.50 ± 0.83 (P ≤ 0.001) with ≤1+ MR in 33/34 patients, including 4 reinterventions for periprosthetic recurrent MR ≥3 without mitral bridge explants or conventional mitral repair or replacement. At 2 years, the mean mitral gradient was 2.15 ± 0.82 mmHg; the mitral annular SLD decreased from 40.4 ± 2.91 mm to 28.9 ± 1.55 mm (P ≤ 0.001). The left ventricular ejection fraction increased (57.9 ± 10.4-62.4 ± 9.7%; P ≤ 0.001). The New York Heart Association functional class improved (2.19 ± 0.76-1.41 ± 0.61; P ≤ 0.001). CONCLUSIONS: The single-centre trial data indicate that direct reduction in the SLD with a mitral bridge is feasible, safe and efficacious in patients with FMR. Validation in a larger population of patients and comparison to conventional annuloplasty ring are necessary. CLINICAL TRIAL REGISTRATION NUMBER: NCT03511716.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Cerny S, Benesova M, Skalsky I, et al. Persistent reduction of mitral regurgitation by implantation of a transannular mitral bridge: durability and effectiveness of the repair at 2 years-results of a prospective trial†. Eur J Cardiothorac Surg. 2019. PMID: 30590416. doi:10.1093/ejcts/ezy423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。